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Aim: The graphene oxide (GO) sheet has been considered one of the most promising 
carbon derivatives in the field of material science for the past few years and has 
shown excellent tumor-targeting ability, biocompatibility and low toxicity. We 
have endeavored to conjugate paclitaxel (PTX) to GO molecule and investigate its 
anticancer efficacy. Materials & Methods: We conjugated the anticancer drug PTX 
to aminated PEG chains on GO sheets through covalent bonds to get GO-PEG-PTX 
complexes. The tissue distribution and anticancer efficacy of GO-PEG-PTX were then 
investigated using a B16 melanoma cancer-bearing C57 mice model. Results: The 
GO-PEG-PTX complexes exhibited excellent water solubility and biocompatibility. 
Compared with the traditional formulation of PTX (Taxol®), GO-PEG-PTX has shown 
prolonged blood circulation time as well as high tumor-targeting and -suppressing 
efficacy. Conclusion: PEGylated graphene oxide is an excellent nanocarrier for 
paclitaxel for cancer targeting.
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Graphene has a hexagonal packed struc-
ture formed by a 2D single layer of carbon 
atoms [1,2]. Owing to its unique properties, 
graphene and its derivatives have attracted 
tremendous attention in the fields of elec-
tronics, energy, materials and biomedical 
applications [3–6]. Although the naked GO 
did not exhibit any obvious in vitro toxicity 
nor in vivo inflammation at low concentra-
tion [7,8], proper surface functionalization is 
essential to design graphene-based nanocar-
rier systems with high solubility in the physi-
ological fluids and acceptable biocompatibil-
ity for biomedical application in physiological 
environments. Various types of hydrophilic 
polymers have been utilized to functionalize 
graphene oxide (GO) using covalent or non-
covalent bonding [9]. Functionalized GO has 
been used for drug and gene delivery [9–21], 
as well as in biosensor platforms, photother-
mal therapy and in tumor and cell imag-
ing [11,22–32]. Numerous types of polymers 
and molecules are possible to use for modify-
ing the surfaces of GO via hydrogen bond-
ing or π–π interactions [9,33]. Many aromatic 
chemotherapy drug molecules can be conju-
gated onto the surface of GO through physi-
cal adsorption, resulting in changing GO 
from poorly soluble sheets to water-soluble 
conjugates [10–12,34]. Dai et al. first loaded a 
water insoluble anticancer analog of camp-
tothecin (CPT) onto GO surface through 
noncovalent conjugation via π–π interac-
tion. The GO loaded with SN38 exhibited 
acceptable biocompatibility and excellent 
solubility both in aqueous and physiologi-
cal solutions [10]. Several research groups 
have studied targeted delivery of doxorubicin 
(DOX) and CPT attached to surface modi-
fied GO, which exhibited superior anticancer 
efficacy [12,16,19,21,34]. Despite its lower optical 
properties, the 2D shape and ultra-small sizes 
of GO may offer many advantages compar-
ing with other carbon-based nanomaterials 
such as single-walled nanotubes (SWNTs). 
For example, the in vitro toxicity of graphene 
towards human cells appears to be lower than 
that of SWNTs. Moreover, the photothermal 
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anticancer efficacy of graphene is superior to that of 
SWNT because of the better dispersion and smaller 
size of graphene nanoparticles.
Liu et al. have first reported that GO modified by coat-
ing its surfaces with PEG (GO-PEG) can become highly 
aqueous soluble and stable in physiological fluids such as 
serum [10]. These findings can make the in vivo intra-
venous application of GO feasible. Moreover, GO-PEG 
has shown significant passive tumor-targeting ability, 
which might be ascribed to the enhanced permeability 
and retention effect of tumor tissue [35]. The long-term 
in vivo biodistribution and toxicity investigations have 
demonstrated that GO-PEG exhibited no obvious tissue 
toxicity, and no organ damage or inflammation symp-
toms [35,36], which revealed the superior characteristics 
of GO-PEG compared with uncoated GO [37]. Accord-
ing to Liu et al., following intravenous injection of GO-
PEG, the formulation has accumulated in the reticulo-
endothelial systems (RES) such as liver and spleen and 
were gradually cleared out via renal excretion and biliary 
pathway into feces over time [36,38,39].
Paclitaxel (PTX) is a widely used chemotherapeutic 
drug that promotes tubulin polymerization and forma-
tion of extraordinarily dysfunctional and stable micro-
tubules, disrupting the normal tubule dynamics [40]. 
However, its poor aqueous solubility is a serious limita-
tion that prevents proper formulation and clinical appli-
cation of the drug [41]. In order to overcome low aqueous 
solubility of PTX, formulations based on Cremophor 
EL (e.g., Taxol®) have been prepared and used via slow 
intravenous infusion following dilution with NaCl 
(0.9%) or dextrose (5%) solutions. However, the sol-
vent system mainly Cremophor EL in Taxol causes seri-
ous toxicological effects [42] such as neurotoxicity and 
nephrotoxicity, which may significantly reduce the over-
all therapeutic benefit of PTX. Therefore, Cremophor 
EL-free delivery systems of PTX have been proposed, 
including those based on polymeric nanoparticles, poly-
meric micelles, liposomes and many prodrug formula-
tions [43–47]. Owing to the advantages and unique per-
formance of GO as a targeting system, formulations of 
PTX loaded onto modified GO are worth exploring.
Unlike DOX and CPT, PTX has no extend π-structure 
larger than one aromatic ring [48]; hence, it is difficult to 
load PTX onto GO by physical adsorption. Even though 
some paper has reported the successful noncovalent con-
jugation of PTX and GO [49], the loading capacity may 
be optimized using other methods. Thus, we have inves-
tigated the possibility of loading PTX onto GO-PEG 
through covalent conjugation, aiming to improve the 
drug physiological solubility and enhance the formula-
tion compatibility and cancer targeting ability. In this 
work we used GO-PEG as a drug carrier to load PTX via 
an ester bond, which is cleavable after in vivo injection. 
The covalent conjugation has been reported to be suc-
cessful at attaching PTX to SWNTs and α,β-Poly(N-
2-hydroxyethyl)-DL-aspartamide (PHEA) [41,50]. The 
influence of GO-PEG-PTX conjugation on drug solu-
bility in water and mouse serum was investigated. More-
over, further in vivo investigations were carried out to 
evaluate the anticancer efficacy of GO-PEG-PTX, the 
blood circulation time, drug bioavailability, tissue distri-
bution and tumor-uptake rate. The in vivo biodistribu-
tion of GO-PEG-PTX was also investigated and com-
pared with that of Taxol. To the best of our knowledge, 
this is the first study that demonstrated the feasibility of 
using PEGylated GO as nanocarriers for PTX and inves-
tigated the anticancer activity of the resultant complex 
compared with Taxol.
Experimental section 
Materials
GO was purchased from Tianjin Plannano Technology 
Co., Ltd. Chloroacetic acid was purchased from Fuchen 
Chemical Reagents Factory (Tianjin, China). N-(3-di-
methylamino propyl-N′-ethylcar-bodiimide) hydro-
chloride (EDC-HCl), N-hydroxysuc-cinimide (NHS), 
Succinic anhydride and pyridine were purchased from 
Kelong Chemical Reagents Factory (Chengdu, China). 
PTX and docetaxel were purchased from Hao-xuan 
Biological Technology Co., Ltd (Xi’an, China). Ami-
nated PEG (NH
2
-PEG-NH
2
, Mw = 4000) was pur-
chased from Kaizheng Biological Technology Co., Ltd, 
(Beijing, China). Cholesterol esterase was purchased 
from Shifeng Biological Technology CO., Ltd (Shang-
hai, China). DMEM cell culture medium was bought 
from Thermo Fisher Scientific (MA, USA). fetal bovine 
serum was supplied by Fumeng Gene Co., Ltd (Shang-
hai, China). 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny-
ltetrazolium bromide (MTT) was supplied by Sigma 
(CA, USA). BCA protein assay reagent kit was pur-
chased from Thermo Fisher Scientific.
Cell lines & animals
A549 and B16 melanoma cancer cell lines were pur-
chased from the Type Culture Collection of the Chinese 
Academy of Sciences (Shanghai, China). C57 mouse 
and Wistar rats were provided by Chengdu Dashuo 
Biotechnology Co., Ltd. All procedures with ani-
mals were conducted in accordance with institutional 
animal care and use guidelines.
Carboxylation of GO
To carboxylate GO sheet, GO (10 mg) was added to 
water and sonicated to form an aqueous suspension. 
NaOH (0.12 g/ml) and chloroacetic acid (0.5 g) were 
then added, and the resultant mixture was sonicated 
using probe sonicator for 3 h to form carboxyl group on 
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the surface of GO. GO-COOH suspension was neu-
tralized and purified by centrifugation at 10,000 rpm. 
The supernatant was discarded and the residue was 
washed with water twice.
Modification of GO with aminated PEG
Carboxylated GO was diluted by water (10 ml) and 
then bath sonicated with amino-terminated PEG4000 
(100 mg) for 30 min, followed by addition of N-(3-
dimethylaminopropyl-N′-ethylcarbodiiminde) hydro-
chloride (EDC-HCl) to reach a concentration of 
40 mmol/l. Then the mixture was allowed to react 
overnight. The final reactants were dialyzed in dialysis 
bags (molecular weight cutoff = 100,000) for 4 days to 
obtain the PEGylated GO.
Fourier transform infrared (IR) absorbance spec-
trum, atomic force microscopy and UV-vis spectrum 
were used to identify whether the carboxylation and 
PEGylation were successful.
Synthesis of 2′-O-succinyl-PTX derivative
PTX (200 mg) and succinic anhydride (0.3 g) were 
added to 5 ml of anhydrous pyridine. The solution 
was stirred for 24 h at room temperature. The progress 
of reaction was detected by thin-layer chromatography 
(CH
3
OH/CHCl
2
 1:20 v/v). After that, 6 ml of water 
was added and stirred for 1 h at 60°C. The solvent (pyri-
dine and water) was then evaporated under vacuum at 
55°C using a rotary evaporator (BUCHI Rotavapor R-3). 
The resultant modified PTX was retrieved via extraction 
using ethyl acetate as solvent. Purification of the desired 
compounds was carried out by column chromatography 
on silica gel (the elution phase was CH
3
OH/CHCl
2
 
1:50 v/v). 1H-NMR (CDCl
3
) and LC-MS were employed 
to confirm the chemical structures.
Conjugation between GO-PEG 
& 2′-O-succinyl-PTX
To synthesize GO-PEG-PTX, 2′-O-succinyl-PTX 
(20 mg) and GO-PEG aqueous solution (∼0.4 mg/ml) 
were dissolved in DMSO-water component solvent 
(1:1 v/v) followed by addition of EDC-HCl (50 mg) 
and NHS (50 mg). The resultant solution was stirred 
at 25°C for 6 h, followed by 2 days of dialysis in 
DMSO and another 2 days in water. HPLC was used 
for identification of the conjugation of GO-PEG-PTX.
HPLC analysis
HPLC assay methods were established for the detec-
tion of PTX concentration in cellular uptake, pharma-
cokinetics and biodistribution studies. Analysis was 
performed using Shimadzu instruments (Chiyoda-Ku, 
Kyoto, Japan) consisting of a 50 μl injector loop, a 
CTO-10A column thermostat, two LC-10AT pumps 
and an Diamonsil C18 reverse phase column. The col-
umn effluent was monitored at 227 nm with a flow rate 
of 1 ml/min at 35°C. The mobile phase was composed 
of acetonitrile and water (45: 55 v/v). The total run 
time for each sample was 15 min.
In vitro release behavior of PTX from 
GO-PEG-PTX
GO-PEG-PTX was dissolved in phosphate-buffered 
saline (PBS; pH 7.4), C57 mouse serum or cholesterol 
esterase solution and incubated for 48 h at 37°C. The 
released PTX was separated via ultrafiltration using 
100 kDa MWCO filters, and the retained PTX was 
detected by HPLC at 4, 12, 24 and 48 h incubation.
Cell culture & in vitro toxicity
A549 and B16 melanoma cancer cell lines were cultured 
in DMEM with high glucose supplemented with 10% 
fatal bovine serum, 100 μg/ml of streptomycin and 
100 μg/ml of penicillin. Cells were placed in a humidi-
fied atmosphere containing 5% CO
2
 at 37°C. The cell 
medium was changed every other day. For the in vitro 
cell toxicity study, cells were seeded onto a 96-well bot-
tom plate and incubated at 37°C overnight. The cells 
were then incubated with different concentrations of 
GO-PEG, GO-PEG-PTX or Taxol (all dissolved in 
DMEM with high glucose) and blank DMEM with 
high glucose. After 24 h of incubation, the relative cell 
viability was measured by MTT assay with Fluoroskan 
Ascent FL microplate fluorometer and luminometer 
(Thermo Scientific).
Cellular uptake assay
Both A549 and B16 cells were seeded in 6-well 
plates. The cells were then exposed to GO-PEG-
PTX or Taxol at a range of concentrations (10, 25, 
50, 100 μg/ml) for 2 h at 37°C. Cold PBS (20°C pH 
7.4) was used to wash the cells in order to remove the 
drug molecules that were not taken up by those cells. 
The cells were then digested and collected as the cel-
lular uptake sample, which were centrifuged at 5000 
rpm for 5 min. The cell residue was lysed with radio-
immunoprecipitation assay buffer in order to release 
the intracellular drug. Methanol and 20% of trichlo-
roacetic acid were added to the cell digests, followed 
by centrifugation at 12,000 rpm for 10 min. Super-
natants were collected and analyzed by HPLC. The 
intracellular concentrations of PTX were investigated 
by HPLC assay using the method described earlier. 
Twenty microliters of the cell lysate from each sample 
was taken to determine the total cell protein content 
using reagent kit (Pierce, USA). The uptake rate was 
expressed as the amount of PTX associated with a unit 
weight of cellular protein.
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Figure 1. Characterization of graphene oxide-PEG. (A) Atomic force microscopy showed that all shards in the vision 
were below 50 nm. (B) Fourier transform infrared spectra of GO and GO-PEG. (C) UV-vis spectra of GO and GO-PEG 
at the concentration of 0.05 mg/ml. 
GO: Graphene oxide. 
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Pharmacokinetic study
Female Wistar rats (220 ± 20 g) were randomly divided 
into two groups. The rats received GO-PEG-PTX (GO-
PEG-PTX group) or Taxol (Taxol group) via tail vein at 
a dose equivalent to 2 mg/kg of PTX (n = 5). At 5 min, 
10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h 
intervals after injection, blood samples were taken and 
the plasma was separated by centrifugation at 5000 rpm 
for 5 min. Docetaxel were added to each sample as the 
internal standard and methanol was used to precipitate 
the protein followed by centrifugation at 13,000 rpm 
for 10 min. Supernatants were collected and analyzed by 
HPLC following the method described above.
Animal model & drug efficacy study
Murine B16 melanoma cancer model was established 
by subcutaneous injection of about 1.5 × 106 cells in 
PBS under the right arm of female C57 mice. The 
mice were used for experiments 14 days after injection 
(the tumor volume was about 100 mm3). For the treat-
ment, GO-PEG-PTX or Taxol with a dose equivalent 
to 4 mg/kg of PTX, GO-PEG and the same volume of 
saline were injected via caudal vein for three-times (0, 
3, 6 days after injection). The tumor size was measured 
by a calipher every other day and was calculated as 
V = (tumor length) × (tumor width)2/2. Relative 
tumor volumes were calculated as V/V
0
 (V
0
 was the 
tumor volume before mice were injected with the for-
mulation). The survival rates of each group were then 
calculated to construct the survival rate curve.
Biodistribtion study
Female C57 mice bearing B16 tumor (tumor size was 
about 200 mm3) were intravenously injected with GO-
PEG-PTX or Taxol with a dose equivalent to 50 mg/kg 
of PTX. The mice were sacrificed at 30 min, 1 h, 4 h, 
8 h, 12 h or 24 h after injection. Samples of blood, liver, 
spleen, lung, kidney and tumor were then collected. 
The samples of the animals’ blood were collected in 
heparinized tubes. Tissues were isolated, washed with 
saline and homogenized with twofold volume of 0.9% 
sodium chloride (g/ml). The blood samples and tissues 
homogenates were processed and measured by HPLC 
as described in the pharmacokinetic study.
In vivo toxicity study
Healthy female C57 mice (18∼20 g) were randomly 
assigned into four groups for drug administration. GO-
www.futuremedicine.com 1251
Figure 2. Paclitaxel loading on graphene oxide-PEG. (A) Schematic illustration of paclitaxel modified by succinic 
anhydride at 2′-OH; (B) Schematic illustration showing how graphene oxide was modified by NH2-PEG4k-
NH2and 2′-succinyl paclitaxel was conjugated on graphene oxide-PEG through a cleavable ester bond.
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PEG-PTX or Taxol with a dose equivalent to 4 mg/kg 
of PTX was intravenously injected into the mice in 
each group, and the mice in the other two groups were 
injected with the same volume of GO-PEG or saline 
via tail vein. The same dose of drug was injected every 
5 days after the initial treatment, six-times total. The 
weight of each mouse was recorded every day and the 
curve of the bodyweight change was established after 
the treatment. For histological evaluation, livers and 
spleens of mice were collected 30 days after the initial 
treatment and were fixed in 4% v/v paraformaldehyde 
for 4 days. The samples were taken and stained with 
hematoxylin and eosin (H & E) for examination by 
light microscopy (Axiovert 40 CFL, Carl Zeiss; Jena, 
Germany). For blood chemistry evaluation, blood 
samples were taken as soon as mice were sacrificed. 
The blood samples were centrifuged at 5000 rpm and 
the serum was collected for chemistry analysis.
Results & discussion 
Synthesis of GO-PEG-PTX
To improve the solubility and in vivo properties of GO, 
a variety of modifiers were investigated to conjugate 
to the surface of GO, such as PEG, folic acid, poly-
ethyleneimine, chitosan, etc. [12,13,17,19]. Because PEG 
has been widely used for improving the water solubil-
ity and biocompatibility of many nanomaterials in bio-
medicine, in this study we chose PEG4000 to improve 
the solubility and in vivo behavior of GO. In brief, GO 
was first converted to GO-COOH through sonication 
and carboxylation at the surface of GO. Then NH
2
-
PEG4k-NH
2
 was conjugated with carboxylate groups 
of GO-COOH via amide bond. The carboxylation was 
done to convert the esters and epoxides into carboxyl 
group, by which GO could conjugate with PEG-NH
2
. 
The decoration of GO by PEG significantly improved 
its solubility both in water and physiological solutions. 
Fourier transform IR spectra were used to confirm 
the assigned structure of GO-PEG. The conjugation 
of PEG with GO-COOH through amide bond for-
mation could be verified by the peak at approximately 
2850 cm-1(C-H bond), approximately 1650 cm-1 (C=O 
bond) and approximately 1100 cm-1 (C-O bond; 
Figure 1B). The diameter of each GO-PEG particle was 
below 50 nm and the thickness of each particle was 
up to 1.9 nm as observed by atomic force microscopy 
(Figure 1A). According to the UV-vis spectra, GO-PEG 
possessed both higher near-infrared and visible absorp-
tion than GO did (Figure 1C). The increased optical 
absorption might be caused by hydrolysis of ester bond 
and ring-opening of epoxide groups on the surface of 
GO molecule under the basic synthesis condition dur-
ing the carboxylation step.
To ensure a proper releasing profile of PTX after intra-
venous injection, PTX was conjugated to GO-PEG 
via a cleavable ester bond, which can be hydrolyzed by 
both chemical and enzymatic pathways (Figure 2A). 
As shown in Figure 2B, GO-PEG-PTX complex was 
synthesized by a two-step reaction. First, 2′-O-succi-
nyl-PTX was synthesized, and then 2′-O-succinyl-
1252 Nanomedicine (Lond.) (2015) 10(8)
Figure 3. The drug release profile using graphene oxide-PEG-paclitaxel in phospate-buffered saline solution, 
C57 mouse serum, esterase enzyme solution and heat denatured enzyme solution after 48 h of incubation with 
phospate-buffered saline and serum, respectively, at 37°C. The retained paclitaxel was collected by filtration and 
detected by HPLC.
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PTX was conjugated to GO-PEG. The synthesis of 
2′-O-succinyl-PTX was carried out according to the 
previously reported methods [41,50–52]. As described 
in Figure 2A, the PTX molecule was first linked by its 
2′-hydroxyl terminus with succinic anhydride. Thin-
layer chromatography analysis was used for detecting 
whether free PTX was fully converted to the resultant. 
The unreacted succinic anhydride turned into water 
soluble succinic acid after stirring at 60°C for 1 h. The 
desired compound was obtained by purification using 
a silica gel column. After that, modified PTX was cou-
pled to the terminal amine group of the PEG previously 
being attached on the surface of GO molecule through 
amide bond [50]. As a standard reaction of forming 
amide bond, 2′-O-succiyl-PTX and GO-PEG were dis-
solved in water/DMSO (1:1) mixed solvent and EDC-
HCL and NHS were added as catalysts. After dialysis 
in DMSO and water respectively, the purified GO-
PEG-PTX was analyzed by HPLC method to confirm 
the successful synthesis. According to the HPLC result, 
approximately 0.51 mg of PTX was conjugated on 1 mg 
of GO-PEG. Different from blank PTX, GO-PEG-
PTX exhibited improved solubility both in water and in 
saline. In vitro release study at 37°C indicated that GO-
PEG-PTX displayed excellent stability in PBS solution, 
in which only very low proportion of PTX was released 
from GO-PEG-PTX complex within 48 h (Figure 3). 
The release rate of PTX in C57 mice serum was faster 
than that in PBS (about 30% of total PTX was released 
within 24 h). What is more, the release rate of PTX in 
esterase enzyme solution was much faster than those 
in PBS and serum. While in denatured enzyme solu-
tion, the release rate was similar with that in PBS. So 
the cleavage of ester bond in serum could be ascribed 
to the existence of esterase enzyme. Importantly, the 
relatively moderate release rate might ensure that PTX 
loaded onto GO-PEG would reach the target tissue and 
then release PTX to exert therapeutic effect.
In vitro investigation of GO-PEG-PTX
Cytotoxicity of GO-PEG-PTX was investigated 
using MTT assay with A549 and B16 cancer cell 
lines. As indicated in Figure 4, GO-PEG-PTX exhib-
ited approximately similar cytotoxic efficacy to that 
exhibited by Taxol at relatively high concentrations. 
No obvious cytotoxicity of plain GO-PEG was found 
during the experiments, even at high concentrations. 
These results indicated that loading PTX in GO-PEG 
did not significantly interfere or reduce cytotoxicity of 
PTX against cancer cells.
We then further investigated the cellular uptake of 
GO-PEG-PTX using A549 and B16 cell lines. Some 
previous research investigations have employed fluo-
rescent or radioactive materials to tag GO molecules 
in order to monitor their dynamics following cellar 
uptake [34,50]. In this study, we used HPLC to investi-
gate the cellular uptake rate because the linear chain of 
NH
2
-PEG4k-NH
2
 did not have much room for con-
jugating the fluorescent material, especially when two 
terminals of PEG were occupied by both GO and PTX. 
HPLC method was established to monitor the intracel-
lular drug contents. It was shown in Figure 5 that the 
www.futuremedicine.com 1253
Figure 4. Comparison of cell survival curves for A549 and B16 cells incubated with graphene oxide-PEG, graphene 
oxide-PEG-paclitaxel or Taxol® for 48 h. The cytotoxicity of graphene oxide-PEG-paclitaxel approximated to that 
of Taxol at high drug concentrations.  
#p ≤ 0.01; *p ≤ 0.05.
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intracellular concentration of drug using GO-PEG-
PTX was slightly lower than that of Taxol at low doses. 
However, when the drug concentration was increased 
the intracellular drug content almost reached the same 
level of that seen by Taxol. Both A549 and B16 cell lines 
shared the same tendency. The cellular uptake results 
and the cytotoxicity investigation suggested that the in 
vitro anti-cancer ability of GO-PEG-PTX was compa-
rable to that of Taxol at the relatively high concentra-
tions used. However, the in vitro anticancer ability of 
GO-PEG-PTX was lower than that of Taxol at the rela-
tively low doses. The previous study of Liu et al. showed 
that cytotoxicity of PTX conjugated to SWNTs was 
relatively lower than that of Taxol at certain drug dose 
range (10∼100 μg/ml) [50]. The low cellular uptake rate 
of the PTX on GO-PEG might be attributed to con-
jugation between PTX and GO-PEG. This was con-
firmed previously by Chang et al. who have reported 
that GO alone could hardly be taken up by can-
cer cells [7]. However, GO-PEG could enter the cells 
through energy required endocytosis mechanism [10,38]. 
Thus when conjugated with GO-PEG, PTX was able to 
enter the cancer cells along with GO-PEG-PTX com-
plex through endocytosis. Although the conjugation 
with GO hindered the immediate uptake of PTX by 
the cells, the long blood circulation time offered by con-
jugating the drug to GO-PEG after in vivo treatment 
was highly advantageous at enhancing the anticancer 
efficacy of PTX. Using this strategy, PTX adminis-
tration as GO-PEG-PTX may result in higher drug 
bioavailability and enhanced antitumor effect.
Pharmacokinectic investigation of GO-PEG-PTX
In order to understand the pharmacokinetics of GO-
PEG-PTX, we used HPLC assay to measure PTX con-
centration in plasma at different time intervals after 
intravenous injection of the formulations into Wistar 
rats via tail vein (2 mg/kg). Blood was collected at dif-
ferent time points after injection. The time–concentra-
tion curves of GO-PTX-PEG and Taxol both exhib-
ited a standard two-compartment model. As shown in 
Figure 6, the elimination speed of PTX was relatively 
rapid both in GO-PEG-PTX and Taxol group. Com-
pared with Taxol, longer second phase blood circulation 
half-time, higher bioavailability and lower clearance 
rate were observed for GO-PEG-PTX. The underlying 
reason was that some time is needed for the cleavage of 
ester linkage between PTX and GO-PEG to occur [53].
Biodistribution & in vivo toxicity investigations 
of GO-PEG-PTX
To further evaluate the tumor targeting ability of GO-
PEG-PTX, we studied tissue distribution of GO-PEG-
PTX and Taxol in B16 melanoma cancer bearing C57 
mice. The tissue distribution of GO-PEG-PTX and 
Taxol were measured at 30 min, 1 h, 4 h, 8 h, 12 h and 
24 h after injecting GO-PEG-PTX or Taxol via tail 
veins of B16 tumor-bearing mice. At predetermined 
time points, the blood samples were collected and the 
animals were sacrificed. Tissues including hearts, livers, 
spleens, lungs and kidneys were isolated immediately. 
Plasma or tissue homogenates were extracted by metha-
nol, and then quantitative measurement of PTX was 
done by HPLC. As shown in Figure 7, after intravenous 
administration of GO-PEG-PTX, peak concentrations 
of PTX in tumor were achieved within 4 h (14.2%), 
which was significantly higher than that of Taxol group. 
The concentration of PTX remained relatively high 
even at 24 h (2%) after administration. For other tis-
sues (Figure 8), the liver and kidney reached the highest 
concentration within 0.5 h (28 and 16%), decreasing 
gradually over time. The highest concentration in spleen 
and lung were achieved within 1 h (32 and 6%, respec-
tively). After 24 h of treatment, PTX in liver and spleen 
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Figure 5. Comparison of the cellular uptake of graphene oxide-PEG-paclitaxel and Taxol® using B16 and A549 
cell lines, which generally demonstrated approximate uptake level of graphene oxide-PEG-paclitaxel and Taxol 
at the concentration of 100 μg/ml. (A) In vitro cellular uptake of GO-PEG-PTX and Taxol in A549 cells using a 
range of drug concentrations (10, 25, 50 and 100 μg/ml). Taxol exhibited relatively higher uptake rate at low drug 
concentrations, but the difference between Taxol and GO-PEG-PTX decreased along with the increase in drug 
concentration; they nearly reached the same uptake at 100 μg/ml (#p ≤ 0.01, *p ≤ 0.05). (B) In vitro cellular uptake 
of GO-PEG-PTX and Taxol in B16 cells using a range of drug concentrations (10, 25, 50 and 100 μg/ml); the two 
formulations shared the same trend with that in A549 cells (#p ≤ 0.01, *p ≤ 0.05). 
GO: Graphene oxide; PTX: Paclitaxel.
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remained at moderate levels (7 and 6%, respectively).
By contrast, after intravenous administration of 
Taxol, peak concentrations of PTX in tumor were 
achieved within 8 h (4%), and PTX decreased sig-
nificantly to a very low concentration in tumor at 24 
h postinjection. In the case of other organs (Figure 8), 
at 0.5 h, PTX was widely distributed in liver (56%), 
kidney and lung with negligible concentrations being 
detected in the tumor tissue (0.08%). The drug con-
centration in liver, lung and kidney reached the highest 
within 0.5 h, and then decreased gradually over time. 
The concentration of PTX in spleen remained relatively 
low throughout the detection period, which reached the 
highest amount at 12 h (2%). PTX in all tissues were 
almost cleared completely at 24 h except liver (4%).
The results of tissue distribution of GO-PEG-PTX 
and Taxol reflected the tumor-treatment efficacy and 
main organ accumulation of the two formulations. By 
conjugating with GO-PEG, PTX exhibited a signifi-
cantly different in vivo distribution. PTX given as GO-
PEG-PTX showed higher blood concentration than 
Taxol over the whole time course examined, which was 
consistent with the pharmacokinetic investigation. The 
distinct difference between GO-PEG-PTX and plain 
PTX in physiological solutions could be attributed to 
the prolonged blood circulation. Another obvious dif-
ference in tissue distribution of PTX was the concentra-
tion in spleen. Much higher concentration was found in 
GO-PEG-PTX group compared with that in the Taxol 
group. After injection of GO-PEG-PTX, the PTX con-
centrations were 27-, 25- and 14-times higher than that 
of Taxol at 1, 4 and 8 h, respectively. It was previously 
reported that graphene as well as SWNTs have higher 
accumulating capacity in RES organs such as liver and 
spleen [38,39,50,54,55]. Liu et al. proved that the uptake of 
drug-macromolecular complex such as PTX-SWNTs 
by RES organs could serve as a scavenger system to 
metabolize and eliminate toxic drugs as well as carriers. 
Therefore, when we utilize GO as a drug carrier, the tox-
icity in those organs must be considered. Some reports 
announced that unmodified GO may induce some 
adverse effects [37,56,57]. However, Liu et al. demonstrated 
that no noticeable organ damage or inflammation was 
observed after intravenous injection of GO-PEG into 
mice at a dose of 20 mg/kg [58]. In this study, we have also 
investigated the in vivo toxicity of GO-PEG-PTX and 
made a comparison with that of Taxol, plain GO-PEG 
and saline. After intravenous administration of those 
four formulations, the weight of each C57 mouse was 
recorded every day. According to the results obtained, 
no significant bodyweight change was observed in each 
group 30 days after the treatment (Figure 9B). Blood 
chemistry analysis was performed 30 days after the first 
injection of different formulation. No obvious differ-
ences between the four groups were found (Figure 9A), 
indicating that GO-PEG-PTX did not cause any detect-
able physiological damage to the liver at the given dose. 
Meanwhile, as displayed in Figure 9C, the immunohis-
tochemistry analysis of liver and spleen separated from 
the mouse in each group 30 days after the treatment did 
not show any inflammation or pathological changes. 
According to these results, GO-PEG-PTX has shown to 
be safe for in vivo administration at the dose of 2 mg/kg, 
and its accumulation in RES organs such as liver and 
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Figure 6. The blood circulation curve of Taxol® and graphene oxide-polyethylene glycol-paclitaxel. The 
pharmacokinetic models of both Taxol and graphene oxide-polyethylene glycol-paclitaxel followed the two 
compartment model. The data inserted are the second-phase blood circulation half-time (T1/2), K, AUC within 24 h 
(AUC0–24 h) and clearance rate. 
#p ≤ 0.01, *p ≤ 0.05. 
AUC0–24 h: Area under concentration–time curve within 24 h; GO: Graphene oxide; K: Elimination rate constant; 
PTX: Paclitaxel; T1/2: Second-phase blood circulation half-time.
Parameters GO-PEG-PTX Taxol®
T1/2 (h) 13.9 11.51
K (1/h) 0.23 0.17
AUC0–24 h (μg/1/h) 4409.3 2617
CL (1/h) 0.017 0.031
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spleen did not seem to affect the health condition of 
C57 mice within the time course of the investigation. 
Although the investigations above and other researchers’ 
study proved the safety of the nanocarrier, Singh et al. 
have reported that atomically thin GO sheets could 
induce thrombus [59]. And amine-modified graphene 
can avoid the aggregatory response in platelets [60]. The 
toxicity study over 30 days is not sufficient to prove the 
long-term safety of GO-PEG-PTX. As a consequence, 
the long-term behavior study and more comprehensive 
investigations of GO-PEG-PTX are needed to further 
validate the in vivo safety of this formulation.
It was clearly shown in our data that GO-PEG-PTX 
exhibited much higher PTX uptake rate in tumor tissue 
than that of Taxol by about 5.5-times (1 h), 3.5-times 
(4 h), 3.3-times (8 h) and 2.8-times (12 h; Figure 7). 
Even at 24 h after injection, PTX concentration of GO-
PEG-PTX in tumor remained above 2% (i.e., 12-times 
higher than that of Taxol). The enhanced permeability 
and retention effects of GO could be the main reason 
of the significantly increased PTX distribution in tumor 
using GO-PEG-PTX. It was believed that the leaky 
and tortuous vasculatures of tumor tissue might prefer 
to withhold nanosize materials such as graphene and 
SWNTs. The tumor targeting ability of GO has been 
shown to be stronger than that of SWNTs because of 
their difference in geometrical structure [54,61,62]. The 
longer residence time in the blood of the nanoconju-
gate may contributed to the higher uptake rate but not 
the most important factor. Even though the biodistri-
bution of GO-PEG, of which had a long-term accu-
mulation process lasting for several weeks [38,50], PTX 
loading on GO-PEG was metabolized and excreted 
quickly. The difference between the tissue distribution 
of GO-PEG and GO-PEG-PTX were possibly caused 
by the cleavage of the ester linkage between PTX and 
GO-PEG after injection into the animals. Because the 
same result has also been reported in the biodistribution 
study of PTX-SWNTs [50]. It was believed that the ester 
linkage was cleaved by carboxylesterases mostly in the 
liver [50,53,63,64]. In a word, our study indicated that GO-
PEG-PTX exhibited much longer blood circulation time 
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Figure 7. Concentration–time curves of PTX in different tissues. Relative concentration-time curves of graphene 
oxide-PEG-PTX and Taxol® in different tissues of C57 mice bearing B16 tumors at 0.5, 1, 4, 8, 12 and 24 h after 
intravenous injection (n = 5 for each group at each time point), which were significantly different among all 
groups (p ≤ 0.05).
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and thus much better tumor uptake rate than the formu-
lation of Taxol. These results implied that a lower dosage 
of GO-PEG-PTX might achieve the same anticancer 
efficacy as Taxol did. As a consequence, our novel con-
jugate would reduce the toxicity and side effects of PTX 
in normal organs, hence possibly offering more desirable 
characteristics and better safety profile compared with 
the market available formulation of PTX (Taxol).
In vivo tumor-suppressing investigation of 
GO-PEG-PTX
In order to investigate the in vivo cancer suppressing effi-
cacy of GO-PEG-PTX and compare to that of Taxol, B16 
murine melanoma cancer animal model was established 
for the experiments. Female C57 mice bearing subcutane-
ously implanted B16 tumors were intravenously injected 
with GO-PEG-PTX or Taxol at the equivalent dosage of 
PTX for three-times (0, 3, 6 days after injection), where 
0 day refers to the day of injecting PTX formulations for 
the first time. Two weeks after injection, the tumor vol-
ume and survival condition were recorded every day. The 
results of tumor growth speed showed that the injection 
of GO-PEG-PTX induced significant tumor inhibition 
as compared with that of Taxol (Figure 10A). Taxol can 
only suppress tumor growth at a relatively moderate rate. 
The tumor growth speed showed no difference between 
blank GO-PEG group and saline group, which indicated 
that the blank GO-PEG itself did not have any antican-
cer efficacy. The survival time of each group also shared 
the same tendency with the result of tumor growth speed 
(Figure 10B). Mice in GO-PEG-PTX group had the lon-
gest survival time. The survival time of mice in Taxol 
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Figure 8.  Tissue distribution of graphene oxide-PEG-paclitaxel and Taxol®. Tissue distribution of graphene oxide-
polyethylene glycol-paclitaxel and Taxol in C57 mice bearing B16 tumors at 0.5, 1, 4, 8, 12 and 24 h after intravenous 
injection (n = 5 for each group at each time interval), which were significantly different among all groups (p ≤ 0.05). 
GO: Graphene oxide; PTX: Paclitaxel.
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group was less than that of GO-PEG-PTX group, but 
was longer than those of GO-PEG and saline groups.
It was shown that PTX loading on GO-PEG pos-
sessed significantly improved anticancer efficacy com-
pared with Taxol, which was proved by slowing down 
the tumor growth and the prolonging survival time. 
The significantly higher tumor-suppressing rate of GO-
PEG-PTX might be ascribed to its much higher tumor 
uptake compared with that of Taxol, which was veri-
fied in our biodistribution study. No enhanced tumor-
suppressing effect or longer survival time of mice after 
blank GO-PEG treatment was observed, indicating 
that the GO-PEG material only played a role of drug 
carrier without eliciting any noticeable anticancer effi-
cacy. However, Arya et al. have reported that carbon 
nanostructures such as GO and SWNTs can enhance 
the sensitivity of lung cancer cells to PTX when car-
bon nanostructures and PTX were incubated with cells 
together. Their in vitro study indicated that GO and 
SWNTs had the ability to generate reactive oxygen spe-
cies, which was crucial for PTX induced cell death, as 
potential cotherapeutics for PTX [65]. We believe that 
further in vivo investigations are needed to illuminate 
the anticancer ability of blank GO-PEG using different 
cancer models, and more prolonged course of therapy 
and different experimental conditions.
To the best of our knowledge, using GO as a car-
rier for PTX through covalent conjugation to achieve 
in vivo therapeutic effects is a novel approach to 
improve the physiological solubility, bioavailability and 
tumor targeting ability of PTX. The unique features 
of the surface of GO facilitates the loading of other 
anticancer drugs or photosensitizers [10,14,66], which 
might cause additive or synergistic effects along with 
the anti cancer agent, and the GO-drug complex can 
also absorb near infrared light to achieve photothermal 
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Figure 9. Relative low in vivo toxicity and tissue damage using graphene oxide-polyethylene glycol-paclitaxel. 
(A) Blood chemistry analysis of mice treated with graphene oxide-polyethylene glycol-paclitaxel (GO-PEG-PTX), 
Taxol, GO-PEG and saline for 30 days, which included ALT, AST and ALP. These findings indicate no deviant 
changes in GO-PEG-PTX group compared with other groups. (B) Bodyweight changing curves of C57 mice treated 
with GO-PEG, GO-PEG-PTX, Taxol® or saline for 30 days. No obvious abnormal weight changes were observed 
between the four groups. (C) Histological evaluation of liver and spleen collected from the mouse along with 
collecting the blood for paraffin section and H&E staining. No obvious tissue damage was observed in the liver or 
the spleen when GO-PEG-PTX was injected (magnification 200×). 
GO: Graphene oxide; PTX: Paclitaxel.
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therapy over tumor tissue [22,34]. Those investigations 
can be carried out in the future to improve GO-PTX 
system starting from the highly promising findings 
established in our present investigation.
We have selected B16 melanoma model in the 
experiment because in our laboratory it is commonly 
used in anticancer research, so we have a lot of experi-
ence with it. Moreover, GO-PEG-PTX exhibited bet-
ter anticancer efficacy than PTX against this cancer 
model. However, we feel confident that following the 
presented findings in this manuscript we will continue 
to investigate the anticancer efficacy of GO-PEG-PTX 
using different cancer models.
Even though GO-based nanoconjugate we investi-
gated have a lot of advantages in anticancer efficacy and 
in vivo safety, it still has limitation and lack of preclinical 
and clinical investigation compared with the US FDA 
approved anticancer drug, nab-Taxol. Further investiga-
tions and comparison will be carried out to state that 
the nanoconjugate is amenable to improvement and 
modification due to the advances in GO possesses.
Conclusion & future perspective
In summary, we loaded PTX on GO-PEG carrier sys-
tem through covalent conjugation, and studied the 
therapeutic effects of GO-PEG-PTX in vitro and in 
vivo. Compared with Taxol, GO-PEG-PTX exhibited 
better tumor-suppressing efficacy due to the higher 
uptake rate in tumor tissue. No obvious in vivo tox-
icity or tissue damage was found in mice after intra-
venous injection of GO-PEG-PTX for 30 days. All 
findings in this study indicated that PEGylated GO is 
an excellent nanocarrier for PTX for cancer targeting. 
However, GO still has several issues in need for fur-
ther investigations. In the future the merit of GO may 
possibly have compared with other nano materials, the 
long-term in vivo safety, LD 50 of the conjugate, com-
prehensive comparison with the FDA approved nab-
PTX will be carried out. Moreover, using the nano-
conjugate to load other chemical anticancer drugs and 
functional genes, as well as photothermal and photo-
dynamical therapies may enhance the efficacy of PTX. 
Thus, the research focus on combining two or more 
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Figure 10. The tumor-suppressing efficacy of graphene oxide-polyethylene glycol-paclitaxel after intravenous 
injecting into the cancer bearing mice; each group consisted of ten mice. (A) The changing rate of relative tumor 
volume on tumor-bearing mice after injecting the same PTX dose using GO-PEG-PTX or Taxol®, along with the 
same volume of GO-PEG and saline (#p ≤ 0.01, *p ≤ 0.05; GO-PEG-PTX comparing to Taxol). (B) The survival time of 
tumor-bearing mice after injecting GO-PEG-PTX, Taxol, GO-PEG or saline. 
GO: Graphene oxide; PTX: Paclitaxel
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different anticancer strategies to achieve synergistic 
effect of GO may have a good perspective. Being a 
promising nanocarrier for PTX, GO has a brilliant 
future in anticancer application. We also believe GO 
can attract more novel researches in cancer therapy 
biomedical imaging and biological sensing because of 
its unique properties. 
Financial & competing interests disclosure
The  authors  are  grateful  for  the  financial  support  from  the 
University of Central  Lancashire, United Kingdom and UClan 
Biomedical Technology  (Shenzhen)  Ltd. The authors have no 
other  relevant  affiliations  or  financialinvolvement  with  any 
organization or entity with a financial  interest  in or financial 
conflict with the subject matter or materials discussed  in the 
manuscript apart from those disclosed. 
No writing assistance was utilized in the production of this 
manuscript.
Ethical conduct of research 
The  authors  state  that  they  have  obtained  appropriate  insti­
tutional review board approval or have followed the princi ples 
outlined in the Declaration of Helsinki for all human or animal 
experimental investigations. In addition, for investi gations in­
volving human subjects, informed consent has been obtained 
from the participants involved.
1260 Nanomedicine (Lond.) (2015) 10(8)
Executive summary
Merits of PEGylated graphene oxide applied in anticancer therapy field
•	 Owing to the good water solubility, highly dispersed ability, high drug-loading efficacy and passive 
tumor-targeting ability, graphene oxide (GO) can be used as a carrier to deliver certain drugs into tumor 
tissues.
•	 PEGylation of GO can improve its solubility in saline and biocompatibility. The obtained GO-PEG can be 
utilized for biomedical applications.
Demand for improvement using paclitaxel in anticancer chemotherapy strategy
•	 The side effects, toxicity and severe anaphylaxis of paclitaxel (PTX) injections used in clinic limit their 
application.
•	 PTX was covalently conjugated onto GO-PEG to optimize the solubility and biocompatibility. GO-PEG-PTX can 
delivery PTX molecules to tumor tissues resulting the improved therapeutic effect.
In vivo investigation 
•	 GO-PEG-PTX exhibited prolonged blood circulation time, much higher tumor distribution and better 
anticancer efficacy compared with Taxol®.
•	 GO-PEG-PTX did not show any obvious or severe in vivo toxicity in the current investigation.
Conclusion & future perspective
•	 PEGylated graphene oxide is an excellent nanocarrier to load PTX for cancer targeting. 
•	 More detailed in vivo toxicity investigation will be carried out to improve its safety. 
•	 Further investigations in the future will include other anticancer drugs and differently surface-engineered 
graphene oxide.
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